Skip Navigation



Europace Advance Access published online on November 16, 2008
Europace, doi:10.1093/europace/eun303
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/1/54    most recent
eun303v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ricci, R. P.
Right arrow Articles by Santini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ricci, R. P.
Right arrow Articles by Santini, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

CLINICAL RESEARCH

Remote control of implanted devices through Home MonitoringTM technology improves detection and clinical management of atrial fibrillation

Renato Pietro Ricci*, Loredana Morichelli and Massimo Santini

Department of Cardiology, San Filippo Neri Hospital, Via Martinotti, 20, 00135 Rome, Italy

Aims: To evaluate the impact of Home MonitoringTM (HM) technology on detection and treatment of atrial fibrillation (AF).

Methods and results: One hundred and sixty-six patients (mean age 73 ± 10 years, 112 males) received HM devices [121 pacemakers, 22 implantable cardioverter defibrillators (ICDs), and 23 ICDs combined with cardiac resynchronization therapy]. A nurse consulted the cardioreports on the website and submitted the alerts for AF (new onset AF, persistent AF, and AF burden of >10% for >5 consecutive days) to the physician. During a mean follow-up of 488 ± 203 days, 42 patients (26%) had alerts for AF. Twenty-two patients had no history of AF before implant. In nine patients, no further action was taken. For the remaining 33 patients, an unscheduled follow-up was performed: in 16, antiarrhythmic drug therapy was introduced/modified; in 15, anticoagulation was started; in 2, antiplatelet drugs were introduced; in 7, an external cardioversion was performed; in 2 patients, the device was reprogrammed to avoid intermittent atrial undersensing during AF; and in 4 patients, no further action was taken. In four cases the arrhythmia was not confirmed (false positive). The median time to the first intervention for AF was 50 days (148 days before the scheduled follow-up).

Conclusion: The HM technology allowed early detection of AF in paced patients and early reaction to optimize medical treatment.

Key Words: Home monitoring, Atrial fibrillation, Antiarrhythmic drugs, Anticoagulation, Telecardiology, Cardiac pacing

* Corresponding author. Tel: +39 06 3306 3934, Fax: +39 06 3306 2489, Email: renatopietroricci{at}tin.it

Manuscript submitted 31 July 2008. Accepted after revision 15 October 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
H. Burri and D. Senouf
Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators
Europace, June 1, 2009; 11(6): 701 - 709.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
C. W. Israel
Optimizing the treatment of atrial fibrillation: contributions by remote monitoring
Europace, January 1, 2009; 11(1): 7 - 8.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.